These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15900367)

  • 1. Evaluation of ovulation induction protocols for poor responders undergoing assisted reproduction techniques.
    Ashrafi M; Ashtiani SK; Zafarani F; Samani RO; Eshrati B
    Saudi Med J; 2005 Apr; 26(4):593-6. PubMed ID: 15900367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of repeated spontaneous luteinizing hormone surges in ovarian stimulation for in vitro fertilization.
    Nisker JA; Bloch CL; Tummon IS; Daniel SA; Yuzpe AA
    J Reprod Med; 1993 Jun; 38(6):413-6. PubMed ID: 8331617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
    Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
    Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
    Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
    Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of GnRH-antagonist to IVF-ET for patients with poor ovarian response].
    Wang B; Sun HX; Hu YL; Chen H; Zhang NY
    Zhonghua Nan Ke Xue; 2008 May; 14(5):423-6. PubMed ID: 18572861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study.
    Dal Prato L; Borini A; Coticchio G; Cattoli M; Flamigni C
    Hum Reprod; 2004 Oct; 19(10):2200-5. PubMed ID: 15271868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial.
    Serafini P; Yadid I; Motta EL; Alegretti JR; Fioravanti J; Coslovsky M
    Fertil Steril; 2006 Oct; 86(4):830-8. PubMed ID: 16963040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists.
    Chung K; Krey L; Katz J; Noyes N
    Fertil Steril; 2005 Aug; 84(2):313-8. PubMed ID: 16084870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small doses of LH activity are needed early in ovarian stimulation for better quality oocytes in IVF-ET.
    Drakakis P; Loutradis D; Kallianidis K; Liapi A; Milingos S; Makrigiannakis A; Dionyssiou-Asteriou A; Michalas S
    Eur J Obstet Gynecol Reprod Biol; 2005 Jul; 121(1):77-80. PubMed ID: 15989987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delaying the initiation of progesterone supplementation until the day of fertilization does not compromise cycle outcome in patients receiving donated oocytes: a randomized study.
    Escribá MJ; Bellver J; Bosch E; Sánchez M; Pellicer A; Remohí J
    Fertil Steril; 2006 Jul; 86(1):92-7. PubMed ID: 16818032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF.
    Lainas T; Zorzovilis J; Petsas G; Stavropoulou G; Cazlaris H; Daskalaki V; Lainas G; Alexopoulou E
    Hum Reprod; 2005 Sep; 20(9):2426-33. PubMed ID: 15946995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
    Pirard C; Donnez J; Loumaye E
    Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
    Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.